Back to Agenda
Session 7: Pharmacovigilance of Cannabis and Related Products
Session Chair(s)
Marc Poitras, PHD, MBA
Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau, Health Canada, Canada
Since the legalization of medical/recreational cannabis products, there has been a constant increase of adverse event cannabis related reporting to Health Canada. On June 30th, 2020, Health Canada issued its Guidance to Industry regarding Cannabis Adverse Reaction Reporting. In this session, representatives from Health Canada, and the Industry will discuss the specific aspects of Cannabis Pharmacovigilance focusing on the implementation of the new Guidance and will address questions/challenges stemming from the experience thus far in relation to the application of the Guidelines.
Learning Objective : At the conclusion of this session, participants should be able to:
- Understand the Guidance to Industry Regarding Cannabis Adverse Reaction Reporting
- Develop Procedures to Enable your Company to React Appropriately to Reports of Adverse Reactions, Including the Activities of Monitoring, Reporting, Assessing, and Understanding their Nature in Order to Minimize Preventable Harms Associated with Cannabis Use
Speaker(s)
Robert Pawinski, MED, MHA, MSN
Chief Medical Officer, R&R Executive Consulting, United Kingdom
Stephanie Jack, MSC
Scientific Manager, Health Canada, Canada
Chanez Narimene Kebache, MBA
Director, Global Product Safety & Pharmacovigilance, Canopy Growth Corporation, Canada
Have an account?